Pirtobrutinib
- Generic Name
- Pirtobrutinib
- Brand Names
- Jaypirca
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21F4N5O3
- CAS Number
- 2101700-15-4
- Unique Ingredient Identifier
- JNA39I7ZVB
- Background
Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481 (Cys481) amino acid wi...
- Indication
Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
- Associated Conditions
- Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma
- Associated Therapies
- -
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Australasian Leukaemia and Lymphoma Group
- Target Recruit Count
- 42
- Registration Number
- NCT05833763
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Sir Charles Gairdener, Nedlands, Western Australia, Australia
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT05734495
- Locations
- 🇺🇸
Beth Israel Deaconness Medical, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Pirtobrutinib and Venetoclax with MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: PirtobrutinibProcedure: Positron Emission TomographyDrug: VenetoclaxProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Biopsy
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 72
- Registration Number
- NCT05677919
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05536349
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05529069
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT05317936
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
🇺🇸Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 650
- Registration Number
- NCT05254743
- Locations
- 🇺🇸
Eisenhower Army Medical Center, Rancho Mirage, California, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
🇺🇸Baylor Scott & White Health, Round Rock, Texas, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05176314
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
🇺🇸QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Loxo Oncology, Inc.
- Registration Number
- NCT05172700
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.